These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25371176)

  • 1. Wild-type KRAS inhibits oncogenic KRAS-induced T-ALL in mice.
    Staffas A; Karlsson C; Persson M; Palmqvist L; Bergo MO
    Leukemia; 2015 May; 29(5):1032-40. PubMed ID: 25371176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
    Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
    J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncogenic Kras initiates leukemia in hematopoietic stem cells.
    Sabnis AJ; Cheung LS; Dail M; Kang HC; Santaguida M; Hermiston ML; Passegué E; Shannon K; Braun BS
    PLoS Biol; 2009 Mar; 7(3):e59. PubMed ID: 19296721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant Ikzf1, KrasG12D, and Notch1 cooperate in T lineage leukemogenesis and modulate responses to targeted agents.
    Dail M; Li Q; McDaniel A; Wong J; Akagi K; Huang B; Kang HC; Kogan SC; Shokat K; Wolff L; Braun BS; Shannon K
    Proc Natl Acad Sci U S A; 2010 Mar; 107(11):5106-11. PubMed ID: 20194733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis.
    Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J
    Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation.
    Zhang J; Wang J; Liu Y; Sidik H; Young KH; Lodish HF; Fleming MD
    Blood; 2009 Feb; 113(6):1304-14. PubMed ID: 19066392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pdx1 expression in hematopoietic cells activates
    Walcheck MT; Nukaya M; Ranheim EA; Matkowskyj KA; Ronnekleiv-Kelly S
    Leuk Lymphoma; 2023 Jun; 64(6):1112-1122. PubMed ID: 37081806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulating Notch counteracts Kras
    Kong G; You X; Wen Z; Chang YI; Qian S; Ranheim EA; Letson C; Zhang X; Zhou Y; Liu Y; Rajagopalan A; Zhang J; Stieglitz E; Loh M; Hofmann I; Yang D; Zhong X; Padron E; Zhou L; Pear WS; Zhang J
    Leukemia; 2019 Mar; 33(3):671-685. PubMed ID: 30206308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nras Q61R/+ and Kras-/- cooperate to downregulate Rasgrp1 and promote lympho-myeloid leukemia in early T-cell precursors.
    Wen Z; Yun G; Hebert A; Kong G; Ranheim EA; Finn R; Rajagoplan A; Li S; Zhou Y; Yu M; Damnernsawad A; Roose JP; Coon JJ; Wen R; Wang D; Zhang J
    Blood; 2021 Jun; 137(23):3259-3271. PubMed ID: 33512434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic
    Osswald L; Hamarsheh S; Uhl FM; Andrieux G; Klein C; Dierks C; Duquesne S; Braun LM; Schmitt-Graeff A; Duyster J; Boerries M; Brummer T; Zeiser R
    Mol Cancer Res; 2021 Sep; 19(9):1596-1608. PubMed ID: 34088868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease.
    Aydin E; Hallner A; Grauers Wiktorin H; Staffas A; Hellstrand K; Martner A
    Oncogene; 2019 Feb; 38(9):1534-1543. PubMed ID: 30323311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Flt3⁺CD150⁻ myeloid progenitors in adult mouse bone marrow that harbor T lymphoid developmental potential.
    Chi AW; Chavez A; Xu L; Weber BN; Shestova O; Schaffer A; Wertheim G; Pear WS; Izon D; Bhandoola A
    Blood; 2011 Sep; 118(10):2723-32. PubMed ID: 21791413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus.
    Li Q; Haigis KM; McDaniel A; Harding-Theobald E; Kogan SC; Akagi K; Wong JC; Braun BS; Wolff L; Jacks T; Shannon K
    Blood; 2011 Feb; 117(6):2022-32. PubMed ID: 21163920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of CD44 attenuates aberrant GM-CSF signaling in Kras G12D hematopoietic progenitor/precursor cells and prolongs the survival of diseased animals.
    Du J; Liu Y; Meline B; Kong G; Tan LX; Lo JC; Wang J; Ranheim E; Zhang L; Chang YI; Ryu MJ; Zhang JF; Zhang J
    Leukemia; 2013 Mar; 27(3):754-7. PubMed ID: 22976127
    [No Abstract]   [Full Text] [Related]  

  • 16. Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.
    Tan Q; Brunetti L; Rousseaux MWC; Lu HC; Wan YW; Revelli JP; Liu Z; Goodell MA; Zoghbi HY
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1511-E1519. PubMed ID: 29382756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Loss of Dnmt3a and endogenous Kras(G12D/+) cooperate to regulate hematopoietic stem and progenitor cell functions in leukemogenesis.
    Chang YI; You X; Kong G; Ranheim EA; Wang J; Du J; Liu Y; Zhou Y; Ryu MJ; Zhang J
    Leukemia; 2015 Sep; 29(9):1847-56. PubMed ID: 25801914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesis.
    Le Roux Ö; Pershing NLK; Kaltenbrun E; Newman NJ; Everitt JI; Baldelli E; Pierobon M; Petricoin EF; Counter CM
    Elife; 2022 Sep; 11():. PubMed ID: 36069770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice.
    Lyubynska N; Gorman MF; Lauchle JO; Hong WX; Akutagawa JK; Shannon K; Braun BS
    Sci Transl Med; 2011 Mar; 3(76):76ra27. PubMed ID: 21451123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
    Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
    Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.